Sandoz/Alza Dynacirc CR
Executive Summary
Alza will manufacture controlled-release isradipine antihypertensive that Sandoz plans to market in the first half of 1995, the companies announce July 13. Dynacirc CR employs Alza's OROS osmotic controlled-release technology that allows once-daily dosing. FDA approved Dynacirc CR June 1. Clinical trials established that the compound "was well-tolerated by patients with mild-to-moderate essential hypertension," the companies say. Sandoz filed the NDA (20-336) for Dynacirc CR in December 1992